Payment overview · 2025
General Payments
$15,068.88
29 reported records · 4 companies
Healthcare provider profile · identity verified
Michael Keith Ackerman, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · WARRENTON, VA · NPI 1174687917
Verified facts
What the public records show
CMS Open Payments records show Michael Keith Ackerman, D.O. received $15,068.88 in general payments during 2025 across 29 reported records.
ARGENX US, INC. accounted for 91.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $13,733.27 | 91.1% | 15 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,252.82 | 8.3% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.12 | 0.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.67 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $11,812.50 | 2 |
| Travel and Lodging | $2,500.89 | 13 |
| Food and Beverage | $755.49 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $13,733.27 | 15 | 2025 |
Source payment records
|
|||||
| ALERE CHOLESTECH LDX Normalized: alere cholestech ldx |
Device | Abbott Laboratories | $815.24 | 3 | 2025 |
Source payment records
|
|||||
| AFINION 2 Normalized: afinion 2 |
Device | Abbott Laboratories | $280.40 | 6 | 2025 |
Source payment records
|
|||||
| AFINION HBA1C DX Normalized: afinion hba1c dx |
Device | Abbott Laboratories | $157.18 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $54.12 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.67 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.67 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 333 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 295 | 76 |
| Metformin Hcl | Metformin Hcl | 285 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 246 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 227 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 207 | 53 |
| Lisinopril | Lisinopril | 199 | 46 |
| Gabapentin | Gabapentin | 174 | 37 |
| Carvedilol | Carvedilol | 158 | 33 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 144 | 36 |
| Losartan Potassium | Losartan Potassium | 138 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 32 |
| Simvastatin | Simvastatin | 111 | 25 |
| Meloxicam | Meloxicam | 109 | 33 |
| Eliquis | Apixaban | 106 | 25 |
| Montelukast Sodium | Montelukast Sodium | 106 | 21 |
| Furosemide | Furosemide | 102 | 27 |
| Sertraline Hcl | Sertraline Hcl | 98 | 27 |
| Omeprazole | Omeprazole | 93 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 22 |
| Allopurinol | Allopurinol | 79 | 20 |
| Januvia | Sitagliptin Phosphate | 78 | 16 |
| Ozempic | Semaglutide | 72 | 12 |
| Alprazolam | Alprazolam | 66 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 14 |
| Synthroid | Levothyroxine Sodium | 63 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 12 |
| Bupropion Xl | Bupropion Hcl | 54 | 14 |
| Tramadol Hcl | Tramadol Hcl | 54 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 13 |
| Prednisone | Prednisone | 52 | 15 |
| Potassium Chloride | Potassium Chloride | 51 | 16 |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 13 |
| Glimepiride | Glimepiride | 49 | 13 |
| Trazodone Hcl | Trazodone Hcl | 49 | 13 |
| Finasteride | Finasteride | 47 | 13 |
| Ezetimibe | Ezetimibe | 46 | suppressed |
| Famotidine | Famotidine | 44 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 40 |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Jardiance | Empagliflozin | 42 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | 11 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 26 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Oxycontin | Oxycodone Hcl | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Alprazolam Xr | Alprazolam | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15,068.88 · 29 records | ARGENX US, INC. | AFINION 2, AFINION HBA1C DX, ALERE CHOLESTECH LDX, EVENITY, NURTEC ODT, PROLIA, VYVGART HYTRULO, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error